Long-form peptide market and regulation intelligence.
Annual reports and deep briefings built for readers, analysts, and journalists who need sourced context without peptide hype.
annual US GLOBAL
State of Peptides 2026
A citation-heavy 2026 report on peptide demand, GLP-1 enforcement, FDA compounding policy, Category 2 peptide risk, and next-generation obesity trials.
Report snapshot
- Published
- May 27, 2026
- Primary focus
- GLP-1 enforcement, 503A/503B compounding status, Category 2 peptide risk, and next-generation obesity trials.
- Editorial posture
- Education only. Not medical advice, prescribing guidance, or vendor endorsement.